Reviews on recent clinical trials · 2013
What about platelet counts in clozapine users?
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Atmaca Murad, Kilic Faruk, Temizkan Abdulgani, Ustundag Bilal
Аннотация
OBJECTIVE: In this retrospective study, we aimed to evaluate platelet changes in patients taking clozapine for a variety of psychiatric disorders and hypothesized that there would be any changes in the course of the treatment.
METHODS: Diagnoses were based on Diagnostic and Statistical Manual of Mental Disorders 4(th) edition. Forty-three patients, with the mean age of 36.23 ± 6.35 years were included into final analysis. Morning venous blood samples were used for platelet counts. Correlation analyses were performed between platelet counts and clozapine doses.
RESULTS: Paired t test did not reveal a significant change in platelet counts at the end visit compared to those of first assessment (p>0.05). Seven (17.9%) of 39 patients had platelet count below 180000 per cubic millimeter at least one time during their clozapine use. In five of these patients, the platelet count returned to a level above 180000 per cubic millimeter, without any dose change or other interventions. On the other hand, as for the issue of increased platelet count, results demonstrated that seven (17.9%) had platelet count above 400000 per cubic millimeter at least one time during clozapine use.
CONCLUSION: The present investigation revealed that platelet changes beyond WBC changes should be taken into consideration when using clozapine. Clinicians should be aware of the deviations from absolute threshold values.
METHODS: Diagnoses were based on Diagnostic and Statistical Manual of Mental Disorders 4(th) edition. Forty-three patients, with the mean age of 36.23 ± 6.35 years were included into final analysis. Morning venous blood samples were used for platelet counts. Correlation analyses were performed between platelet counts and clozapine doses.
RESULTS: Paired t test did not reveal a significant change in platelet counts at the end visit compared to those of first assessment (p>0.05). Seven (17.9%) of 39 patients had platelet count below 180000 per cubic millimeter at least one time during their clozapine use. In five of these patients, the platelet count returned to a level above 180000 per cubic millimeter, without any dose change or other interventions. On the other hand, as for the issue of increased platelet count, results demonstrated that seven (17.9%) had platelet count above 400000 per cubic millimeter at least one time during clozapine use.
CONCLUSION: The present investigation revealed that platelet changes beyond WBC changes should be taken into consideration when using clozapine. Clinicians should be aware of the deviations from absolute threshold values.